行情

CLSN

CLSN

克莱瑞恩
NASDAQ

实时行情|Nasdaq Last Sale

0.3903
-0.0437
-10.07%
盘后: 0.4169 +0.0266 +6.82% 18:53 01/21 EST
开盘
0.4181
昨收
0.4340
最高
0.4400
最低
0.3854
成交量
84.81万
成交额
--
52周最高
3.480
52周最低
0.3854
市值
3,378.35万
市盈率(TTM)
-1.3417
分时
5日
1月
3月
1年
5年
Celsion prices and closes preferred stock offering
Celsion (NASDAQ:CLSN) has priced and closed its registered direct offering of convertible redeemable preferred stock. The company entered into a securities purchase agreement with certain institutional investors to purchase 50,000
Seekingalpha · 01/13 22:38
Celsion Corporation Announces Pricing of $30 Million Registered Direct Offerings of Convertible Redeemable Preferred Stock
LAWRENCEVILLE, N.J., Jan. 13, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, today announced the closing of its previously announced registe...
GlobeNewswire · 01/13 22:30
BRIEF-Celsion Corporation Announces Pricing Of $30 Million Registered Direct Offerings Of Convertible Redeemable Preferred Stock
reuters.com · 01/11 01:48
Celsion Corporation 宣布 3000 万美元可转换可赎回优先股的注册直接发行定价
LAWRENCEVILLE, N.J., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, today announced that it has entered into a securities purchase ...
GlobeNewswire · 01/11 01:45
Celsion Corporation Invited to Present Poster at Cytokine-Based Cancer Immunotherapies Summit
Celsion Corporation’s GEN-1 IL-12 Program in Advanced Ovarian Cancer to be Featured in Poster Presentation Chief Science Officer Dr. Khursheed Anwer to Present and Participate in Two Panel Discussions LAWRENCEVILLE, N.J., Nov. 29, 2021 (GLOBE NEWSWIRE) -- ...
GlobeNewswire · 2021/11/29 13:30
Notable earnings before Monday's open
AVYA, CRNC, KMDA, NIU, TWST For Seeking Alpha's full earnings season calendar, click here.
Seekingalpha · 2021/11/19 15:15
CLSN: OVATION 2 Trial Nears 70% of Target Enrollment…
By David Bautz, PhD NASDAQ:CLSN READ THE FULL CLSN RESEARCH REPORT Business Update Ovation 2 Study Near 70% of Target Enrollment Celsion Corporation (NASDAQ:CLSN) is currently conducting the OVATION 2 clinical trial of GEN-1 in patients with advanced ovari...
Zacks Small Cap Research · 2021/11/17 12:25
BRIEF-Celsion Corporation Reports Third Quarter 2021 Financial Results
reuters.com · 2021/11/15 14:21
更多
财务预测
实际值（美元）
预测值（美元）
利润表更多
净利润（美元）
同比（%）
资产负债表更多
总资产（美元）
总负债（美元）
资产负债率（%）
现金流表更多
经营现金流（美元）
同比（%）
了解CLSN最新的财务预测，通过CLSN每股收益，每股净资产，每股现金流等数据分析克莱瑞恩近期的经营情况，然后做出明智的投资选择。
分析师评级

2位分析师的综合评级

买入

免责声明：分析师观点仅供投资者决策参考，不构成任何买卖投资建议。

0.00%强力推荐
50.00%买入
50.00%中性
0.00%落后大盘
0.00%卖出
目标价格预测
分析师预测CLSN价格均价为3.250，最高价位3.500，最低价为3.000。
最高3.500
均价3.250
最低3.000
现价0.3903
EPS
实际EPS
预期EPS
-0.10-0.08-0.05-0.03
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Q4 2021
机构持股
总机构数: 56
机构持股: 928.29万
持股比例: 10.72%
总股本: 8,655.77万
类型机构数股数
增持
9
104.46万
建仓
6
13.70万
减持
9
35.63万
平仓
7
62.48万
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
生物技术和医学研究
-1.82%
制药与医学研究
-1.11%
高管信息
Chief Financial Officer/Executive Vice President/Secretary/IR Contact Officer
Jeffrey Church
Executive Vice President
Khursheed Anwer
Executive Vice President
Nicholas Borys
Director/Chief Executive Officer/President/Chairman
Michael Tardugno
Director
Stacy Lindborg
Director
Christine Pellizzari
Independent Director
Donald Braun
Independent Director
Augustine Chow
Independent Director
Frederick Fritz
Independent Director
Robert Hooper
暂无数据
  • 全部
  • 财务报告
  • 内部人交易
更多
CLSN 简况
Celsion Corporation (Celsion) 是一家临床阶段的生物技术公司。该公司的产品线包括GEN-1（一种用于局部治疗卵巢癌的基于DNA的免疫疗法）和ThermoDox（一种用于多种癌症适应症的多柔比星热激活脂质体封装）。GEN-1是一种IL-12DNA质粒载体，通过脂质聚合物递送系统形成纳米颗粒，是通过TheraPlas平台技术设计的候选产品。该公司的溶血脂热敏脂质体(LTSL)技术是一种热敏脂质体制剂，可在温和的热量存在下通过治疗来治疗疾病。TheraSilence技术提供合成生成的抑制性RNA(RNAi)，以调节靶细胞中的蛋白质表达。

微牛提供Celsion Corporation(NASDAQ-CLSN)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的CLSN股票新闻，以帮助您做出投资决策。

模拟交易：模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易CLSN股票基本功能。